Baird 'Incrementally Positive' on Sarepta (SRPT) Following 'Shocking Move' by FDA

Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom

Sarepta Therapeutics (NASDAQ: SRPT) has been halted ahead of today FDA AdCom to review the New Drug Application (NDA) for eteplirsen.

After plunging last Thursday on negative-biased FDA briefing documents, shares surged on Friday on positive draft questions.

Sarepta Therapeutics (SRPT) Active Ahead of Today's FDA AdCom and Expected Halt

Sarepta Therapeutics (NASDAQ: SRPT) is trading up ahead of today's FDA AdCom. After plunging Thursday on negative biased briefing documents, shares surged on Friday on positive draft questions. Shares may be halted shortly ahead of the panel.

Sarepta (SRPT) Voting Questions Rekindle Hope, but RBC Still Expects a Negative Panel

RBC Capital analyst, Simos Simeonidis, weighed in Sarepta Therapeutics (NASDAQ: SRPT) after the FDA posted 5 voting questions and explanatory discussion points ahead of Monday's eteplirsen panel.

"We view the fact that panel members will have to vote on Monday as an incremental positive for SRPT, simply because of the understandable pressure committee members will be under, in the presence of the DMD... More

FDA Draft Questions Changes Calculus on Sarepta (SRPT) Approval 'to Some Extent' - Janney Montgomery Scott

Janney Montgomery Scott weighed in on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA released draft questions which re-ignited optimism for a positive outcome surrounding eteplirsen.

The analyst first notes there was not clear voting questions during BioMarin's drisapersen review.... More

Leerink Remains Skeptical Despite FDA Draft Questions on Sarepta (SRPT)

Leerink Partners analyst Joseph Schwartz weighed in on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA released draft questions which re-ignited optimism for a positive outcome surrounding eteplirsen.

"Although voting question #7 could appear to imply a possible positive vote (and an... More

Unusual 11 Mid-Day Movers 4/22: (AMD) (NGL) (SRPT) Higher; (RCKY) (EGT) (TRXC) Lower

Advanced Micro Devices (Nasdaq: AMD) 36.1% HIGHER; reported Q1 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $832 million versus the consensus estimate of $818.16 million. For Q2 2016, AMD expects revenue to increase 15 percent, plus or minus 3 percent, sequentially.

NGL Energy Partners (NYSE: NGL) 33.9% HIGHER; announced a $200 million private placement of 10.75% Class A Convertible Preferred Units and formation of a strategic relationship with funds managed by Oaktree Capital Management L.P.

Sarepta Therapeutics... More

Sarepta Therapeutics (SRPT) Resumes Trading Following Volatility Spike

Sarepta Therapeutics (NASDAQ: SRPT) resumes trading after the volatility pause as FDA adds voting questions, which were viewed favorably. Shares last up 25%.

Sarepta Therapeutics (SRPT) triggers limit-up, limit-down trading pause

Sarepta Therapeutics (NASDAQ: SRPT) triggers limit-up, limit-down trading pause.

Sarepta Therapeutics (SRPT) Continues Surge Higher as FDA Ads Voting Question

Sarepta Therapeutics (NASDAQ: SRPT) ads to gains. Chatter the FDA adding a voting question. Now up 30%

Sarepta Therapeutics (SRPT) Sees Strong Mid-Day Upside

Sarepta Therapeutics (NASDAQ: SRPT) is seeing nice upside movement mid-day after getting slaughtered yesterday on the FDA briefing document. The AdCom is Monday 04/25. Shares last traded up 11% to $12.23.